

PRESS RELEASE

Veeda Oncology Announces \$10.2 million of New Business

25 November 2008: Veeda Oncology, a full service global Oncology CRO with facilities in North America, Europe and India, has been awarded \$10.2 million of new clinical research programs during the past 30 days from five new clients.

The awarded work includes services for site management, project management, data management, pharmacovigilance, medical oversight, biostatistical support and monitoring services. The awarded work will be conducted in North America, Europe and India.

Matt Bowman, President and CEO of Veeda Oncology, stated “this continued growth is a reflection of the need within oncology clinical development for oncology expertise, cost effective programs and access to oncology patients”.

Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service Oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.

Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research (Veeda CR), which is a leading CRO specializing in the early clinical development of drugs. With state of the art clinical pharmacology units in the UK, Europe and India, fully accredited GLP Laboratories and an established Biometrics team in Belgium and India, Veeda CR is able to offer clients a full range of phase I and IIa services.

For further information, please contact:

Priyanka Shah
Veeda Clinical Research
+91 9879068886
priyanka.shah@veedacr.com